Cargando…
Clinical relevance of lymph node ratio in breast cancer patients with one to three positive lymph nodes
BACKGROUND: To test the hypotheses that breast cancer patients with one to three positive lymph nodes (pN1) consist of heterogeneous prognostic subsets and that the ratio of positive nodes to total nodes dissected (lymph node ratio, LNR) might discriminate patients with a higher risk as candidates f...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778309/ https://www.ncbi.nlm.nih.gov/pubmed/23942073 http://dx.doi.org/10.1038/bjc.2013.465 |
_version_ | 1782285093675466752 |
---|---|
author | Kim, S I Cho, S-H Lee, J S Moon, H-G Noh, W C Youn, H J Ko, B K Park, B-W |
author_facet | Kim, S I Cho, S-H Lee, J S Moon, H-G Noh, W C Youn, H J Ko, B K Park, B-W |
author_sort | Kim, S I |
collection | PubMed |
description | BACKGROUND: To test the hypotheses that breast cancer patients with one to three positive lymph nodes (pN1) consist of heterogeneous prognostic subsets and that the ratio of positive nodes to total nodes dissected (lymph node ratio, LNR) might discriminate patients with a higher risk as candidates for post-mastectomy radiation therapy (PMRT). METHODS: Using information from 7741 node-positive patients, we first identified cutoff values of the LNR using the nonparametric bootstrap method. Focusing on 3477 patients with pN1 disease, we then evaluated the clinical relevance of the LNR categorised by the estimated cutoff values (categorised LNR, cLNR). RESULTS: Among 3477 patients with pN1 disease, 3059 and 418 patients were assigned into the low and intermediate cLNR groups, respectively, based on a cutoff value of 0.18. The prognostic factors associated with poor overall survival (OS) included younger age, T2 stage, negative oestrogen/progesterone receptors, high histologic grade, and intermediate cLNR. Post-mastectomy radiation therapy significantly increased OS in patients assigned to the intermediate cLNR (hazard ratio, 0.39; 95% confidence interval, 0.17–0.89; P=0.0248), whereas patients in the low cLNR group derived no additional survival benefit from PMRT. CONCLUSION: This study suggests that PMRT should be recommended for patients with pN1 disease and an intermediate cLNR. |
format | Online Article Text |
id | pubmed-3778309 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-37783092013-09-23 Clinical relevance of lymph node ratio in breast cancer patients with one to three positive lymph nodes Kim, S I Cho, S-H Lee, J S Moon, H-G Noh, W C Youn, H J Ko, B K Park, B-W Br J Cancer Clinical Study BACKGROUND: To test the hypotheses that breast cancer patients with one to three positive lymph nodes (pN1) consist of heterogeneous prognostic subsets and that the ratio of positive nodes to total nodes dissected (lymph node ratio, LNR) might discriminate patients with a higher risk as candidates for post-mastectomy radiation therapy (PMRT). METHODS: Using information from 7741 node-positive patients, we first identified cutoff values of the LNR using the nonparametric bootstrap method. Focusing on 3477 patients with pN1 disease, we then evaluated the clinical relevance of the LNR categorised by the estimated cutoff values (categorised LNR, cLNR). RESULTS: Among 3477 patients with pN1 disease, 3059 and 418 patients were assigned into the low and intermediate cLNR groups, respectively, based on a cutoff value of 0.18. The prognostic factors associated with poor overall survival (OS) included younger age, T2 stage, negative oestrogen/progesterone receptors, high histologic grade, and intermediate cLNR. Post-mastectomy radiation therapy significantly increased OS in patients assigned to the intermediate cLNR (hazard ratio, 0.39; 95% confidence interval, 0.17–0.89; P=0.0248), whereas patients in the low cLNR group derived no additional survival benefit from PMRT. CONCLUSION: This study suggests that PMRT should be recommended for patients with pN1 disease and an intermediate cLNR. Nature Publishing Group 2013-09-03 2013-08-13 /pmc/articles/PMC3778309/ /pubmed/23942073 http://dx.doi.org/10.1038/bjc.2013.465 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Clinical Study Kim, S I Cho, S-H Lee, J S Moon, H-G Noh, W C Youn, H J Ko, B K Park, B-W Clinical relevance of lymph node ratio in breast cancer patients with one to three positive lymph nodes |
title | Clinical relevance of lymph node ratio in breast cancer patients with one to three positive lymph nodes |
title_full | Clinical relevance of lymph node ratio in breast cancer patients with one to three positive lymph nodes |
title_fullStr | Clinical relevance of lymph node ratio in breast cancer patients with one to three positive lymph nodes |
title_full_unstemmed | Clinical relevance of lymph node ratio in breast cancer patients with one to three positive lymph nodes |
title_short | Clinical relevance of lymph node ratio in breast cancer patients with one to three positive lymph nodes |
title_sort | clinical relevance of lymph node ratio in breast cancer patients with one to three positive lymph nodes |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778309/ https://www.ncbi.nlm.nih.gov/pubmed/23942073 http://dx.doi.org/10.1038/bjc.2013.465 |
work_keys_str_mv | AT kimsi clinicalrelevanceoflymphnoderatioinbreastcancerpatientswithonetothreepositivelymphnodes AT chosh clinicalrelevanceoflymphnoderatioinbreastcancerpatientswithonetothreepositivelymphnodes AT leejs clinicalrelevanceoflymphnoderatioinbreastcancerpatientswithonetothreepositivelymphnodes AT moonhg clinicalrelevanceoflymphnoderatioinbreastcancerpatientswithonetothreepositivelymphnodes AT nohwc clinicalrelevanceoflymphnoderatioinbreastcancerpatientswithonetothreepositivelymphnodes AT younhj clinicalrelevanceoflymphnoderatioinbreastcancerpatientswithonetothreepositivelymphnodes AT kobk clinicalrelevanceoflymphnoderatioinbreastcancerpatientswithonetothreepositivelymphnodes AT parkbw clinicalrelevanceoflymphnoderatioinbreastcancerpatientswithonetothreepositivelymphnodes |